Dr. Agarwal's Health Care earnings calls.

Dr. Agarwal's Health Care delivered a strong Q3 FY26 with revenue from operations growing 23% YoYCurrent 23% vs previous available quarter 20.8%. to ₹530 croreCurrent reported value: ₹530 crore. No comparable prior figure is available in the source record., driven by volume and value growth. EBITDA grew 21.3% YoYCurrent reported value: 21.3% YoY. No comparable prior figure is available in the source record. to ₹155 croreCurrent reported value: ₹155 crore. No comparable prior figure is available in the source record. with margins stable at 28.4%Current reported value: 28.4%. No comparable prior figure is available in the source record., while PAT surged 55% YoYCurrent reported value: 55% YoY. No comparable prior figure is available in the source record. to ₹44 croreCurrent reported value: ₹44 crore. No comparable prior figure is available in the source record. aided by lower finance costs. Surgical volumes grew 11.6% YoY, with high-end cataract procedures rising to 28%Current 28%. Reported change: +340bps YoY. of cataract revenue and robotic cataract surgeries up 83% YoY. The company added 38 new facilities in 9M FY26 and plans 16 more in Q4, targeting 55-60 annual additions. Management reiterated confidence in meeting full-year guidance. Key risk: slower-than-expected ramp-up in newer geographies like Delhi and Ethiopia could pressure near-term margins.